Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma CLINICAL OBSERVATION Treatment With -Blockers and Reduced Disease Progression in Patients With Thick Melanoma Vincenzo De Giorgi, MD; Marta Grazzini, MD; Sara Gandini, PhD; Silvia Benemei, MD; Torello Lotti, MD; Niccolò Marchionni, MD; Pierangelo Geppetti, MD reclinical evidence shows that -adrenoceptor antagonists (-blockers) inhibit tumor and metastasis progression in animal models of melanoma. We hypothesized that the use of -blockers for concomitant diseases is associated with a reduced risk of progression of thick P (Breslow thickness 1 mm) malignant melanoma. Two patient subgroups were identified from the medical records of 121 consecutive patients with a thick melanoma. Of these, 30 patients had been prescribed -blockers for 1 year or more (treated subgroup), whereas the other 91 were un- treated. After a median follow-up time of 2.5 years, tumor progression was observed in 3.3% of the treated subgroup and in 34.1% of the untreated subgroup. The Cox model on progression indicated a 36% (95% confidence interval, 11%-54%) (P =.002) risk reduction for each year of -blocker use. No deaths were observed in the treated group, whereas in the untreated group 24 patients died. To our knowledge, the present study suggests for the first time that exposure to-blockers for 1 year http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma

Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/treatment-with-blockers-and-reduced-disease-progression-in-patients-J7VBfvIE9G

References (10)

Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2011.131
pmid
21518948
Publisher site
See Article on Publisher Site

Abstract

CLINICAL OBSERVATION Treatment With -Blockers and Reduced Disease Progression in Patients With Thick Melanoma Vincenzo De Giorgi, MD; Marta Grazzini, MD; Sara Gandini, PhD; Silvia Benemei, MD; Torello Lotti, MD; Niccolò Marchionni, MD; Pierangelo Geppetti, MD reclinical evidence shows that -adrenoceptor antagonists (-blockers) inhibit tumor and metastasis progression in animal models of melanoma. We hypothesized that the use of -blockers for concomitant diseases is associated with a reduced risk of progression of thick P (Breslow thickness 1 mm) malignant melanoma. Two patient subgroups were identified from the medical records of 121 consecutive patients with a thick melanoma. Of these, 30 patients had been prescribed -blockers for 1 year or more (treated subgroup), whereas the other 91 were un- treated. After a median follow-up time of 2.5 years, tumor progression was observed in 3.3% of the treated subgroup and in 34.1% of the untreated subgroup. The Cox model on progression indicated a 36% (95% confidence interval, 11%-54%) (P =.002) risk reduction for each year of -blocker use. No deaths were observed in the treated group, whereas in the untreated group 24 patients died. To our knowledge, the present study suggests for the first time that exposure to-blockers for 1 year

Journal

JAMA Internal Medicine – American Medical Association

Published: Apr 25, 2011

There are no references for this article.